Horizon Pharma plc to Participate in Two Conferences in February
(firmenpresse) - DUBLIN, IRELAND -- (Marketwired) -- 01/29/15 -- Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that Timothy P. Walbert, chairman, president and chief executive officer, will present at the following conferences in February.
Presentation Date: Tuesday, February 10, 2015
Presentation Time: 1:30pm E.T.
Presentation Date: Thursday, February 12, 2015
Presentation Time: 3:05pm E.T.
The presentations will be webcast live and may be accessed by visiting Horizon's website at . A replay of the webcast will be available for 10 business days.
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. Horizon's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon's global headquarters are in Dublin, Ireland. For more information, please visit .
Robert F. Carey
Executive Vice President, Chief Business Officer
+1 224-383-3250
Geoff Curtis
+1 312-233-1253
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.01.2015 - 21:05 Uhr
Sprache: Deutsch
News-ID 367977
Anzahl Zeichen: 0
contact information:
Town:
DUBLIN, IRELAND
Kategorie:
Drugs
Diese Pressemitteilung wurde bisher 251 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Horizon Pharma plc to Participate in Two Conferences in February"
steht unter der journalistisch-redaktionellen Verantwortung von
Horizon Pharma plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
